Drug Database
PO

polio vaccine

✓ Approved

Sanofi S.A · Vaccine · Vaccine

What is polio vaccine?

polio vaccine is a vaccine developed by Sanofi S.A. It is approved for therapeutic indications via unknown.

Drug Profile

CompanySanofi S.A
Drug ClassVaccine, Large Molecules
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Sanofi S.A

Therapeutic Indications

polio vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresPolio immunisation✓ Approved

Related Research Articles

PubMedFrontiers in veterinary science2026-07-17

A trivalent inactivated PDCoV-PEDV-TGEV vaccine confers protective efficacy in piglets coinfected with porcine rotavirus.

Zha Yinhe Y, Yu Xiaoyu X, Duan Yu Y, Zhang Wentao W et al.

Porcine epidemic diarrhea virus (PEDV), porcine deltacoronavirus (PDCoV), and transmissible gastroenteritis virus (TGEV) are the primary enteric coronaviruses responsible for viral diarrhea in piglets. These pathogens frequently co-circulate with porcine rotavirus (PoRV) under field conditions, leading to increased disease severity and complicating prevention efforts. Although multivalent vaccines targeting these three coronaviruses have been developed, their protective efficacy in the presence of PoRV coinfection remains largely unknown. Based on our previously developed trivalent inactivated PDCoV-PEDV-TGEV vaccine, the present study evaluated its immunoprotective efficacy in piglets naturally infected with PoRV. The results showed that, despite the background of persistent PoRV infection, the trivalent vaccine induced detectable neutralizing antibodies against PEDV, PDCoV, and TGEV (titers≥1:64). Furthermore, vaccination significantly reduced fecal viral shedding after challenge, shortened the duration of diarrhea, and alleviated intestinal pathological damage. Immunofluorescence assays confirmed that antigen deposition of the target coronaviruses in the intestines of vaccinated piglets was markedly reduced. However, vaccinated piglets continued to shed PoRV, indicating that the vaccine did not confer sterilizing immunity but rather reduced clinical severity. This study provides the experimental evidence that the trivalent inactivated vaccine confers effective protection against the three major porcine enteric coronaviruses even under complex clinical conditions involving PoRV coinfection. These findings offer important insights for developing immunization strategies to control multi-pathogen infections in swine production.

PMID 42465716
Read full article →
PubMedVaccine2026-07-17

Protective immunity of lectin-adjuvanted intraperitoneal injection vaccine against Aeromonas veronii infection in Oreochromis niloticus.

Guha Ritam R, Wangkahart Eakapol E, Elumalai Preetham P

Disease outbreaks caused by Aeromonas veronii pose a significant threat to Nile tilapia (Oreochromis niloticus) aquaculture. Lectin-based adjuvants, such as concanavalin A (ConA), can potentially enhance vaccine efficacy by stimulating both innate and adaptive immunity. This study evaluated the immunoprotective potential of a ConA-adjuvanted, formalin-inactivated A. veronii vaccine administered intraperitoneally. Nile tilapia were vaccinated intraperitoneally with the inactivated A. veronii vaccine formulated with ConA. Safety was assessed by monitoring fish behavior and physiological responses. Innate immune activation was evaluated through lysozyme (LZM), myeloperoxidase (MPO), and superoxide dismutase (SOD) assays. Humoral response was measured via serum IgM levels. Gene expression in head kidney and spleen tissues was analyzed for TCR-β, IgM, MHC -II, CD4, and proinflammatory cytokines (IL-1β, IL-8). Protective efficacy was determined by challenging vaccinated fish with live A. veronii and calculating relative percent survival (RPS). The vaccine was safe, with no adverse effects observed. Vaccinated fish showed significant increases in LZM, MPO, and SOD activities, indicating enhanced innate immunity. Serum IgM levels peaked at 42 days post-vaccination, demonstrating robust humoral response. Gene expression analysis revealed upregulation of immune markers confirming activation of humoral (IgM), proinflammatory cytokine (IL-1β, IL-8) and cell-mediated pathways (TCR-β, MHC-II, CD4). Following challenge, the ConA-adjuvanted vaccine group exhibited the highest RPS (79%), significantly higher than controls. These results highlight the potent immunostimulatory effect of ConA and the vaccine's capacity to bridge innate and adaptive immunity in Nile tilapia. The adjuvant effects of ConA have improved the vaccine efficacy and immunogenicity.

PMID 42462678
Read full article →
PubMedNeuropsychological rehabilitation2026-07-17

Chess-based cognitive remediation training as an add-on intervention treatment for alcohol use disorder: A quasi-randomized clinical trial.

Seeger Alexandra A, Kinzel Alexander A, Matthiae Kathrin K, Schmitt Roland R et al.

Alcohol use disorder (AUD) is associated with deficits in various cognitive functions which can impair conventional treatment and increase relapse risk. This longitudinal quasi-randomized controlled study investigated chess-based cognitive remediation training (CB-CRT) as add-on therapy to improve cognitive control and psychosocial outcomes compared to standard rehabilitation. Patients in the EG attended 90-minute CB-CRT group sessions twice weekly for six weeks. Assessments were conducted at baseline (T1, day 1), post-intervention (T2, day 42), and on day 126 (T3). Cognitive measures, abstinence, craving, subjective well-being, and liking of the intervention were assessed. Fifty-one participants completed two timepoints (T2 six weeks after T1): n = 32 allocated to the EG and n = 19 to the CG (no chess intervention). The CB-CRT group showed modest improvement in sustained attention at T2. No significant effects were found for short-term abstinence, craving, or mood at T3. General life satisfaction increased in the CB-CRT group at T2, but this effect was not maintained at follow-up. The intervention was well accepted, with recommendation ratings increasing over time, suggesting CB-CRT is a feasible, low-cost add-on option for AUD rehabilitation.

PMID 42464526
Read full article →
PubMedBMC veterinary research2026-07-17

Design and immunoinformatics characterization of a novel multi-epitope vaccine rPRRSV-35N targeting NADC30-like and NADC34-like porcine reproductive and respiratory syndrome virus variants.

Xu Dawei D, Wang Hefei H, Li Miao M, Zhang Ying Y et al.

Porcine reproductive and respiratory syndrome (PRRS), caused by the genetically diverse porcine reproductive and respiratory syndrome virus (PRRSV), remains a major economic burden to the global swine industry. Current commercial vaccines, including modified live virus (MLV) and inactivated vaccines, have shown limited effectiveness against newly emerging PRRSV variants, particularly NADC30-like and NADC34-like strains. There is therefore a need for improved vaccine strategies targeting these circulating strains. In this study, we used immunoinformatics approaches to design a multi-epitope vaccine candidate, rPRRSV-35N, against PRRSV NADC30-like and NADC34-like strains, based on antigenic profiling and prediction of T- and B-cell epitopes. This multi-epitope vaccine candidate integrates six cytotoxic T lymphocyte (CTL) epitopes, three helper T lymphocyte (HTL) epitopes, and seven linear B-cell epitopes (LBE). The epitopes were linked sequentially by flexible linkers. Porcine β-defensin-2 (PBD-2) and PADRE epitopes were incorporated to potentially improve immunogenicity. In silico prediction showed an antigenicity score of 0.6597 and a solubility probability of 0.530. It showed no toxicity or allergenicity, with a molecular weight of 36.64 kDa and a theoretical isoelectric point (pI) of 9.81. Molecular docking and normal mode analysis indicated stable interactions with TLR2 and TLR4 receptors. Immunoinformatics simulations further revealed that the candidate has the potential to induce both humoral and cellular immune responses. The construct was designed for in silico cloning into pET28a(+), and the plasmid was commercially synthesized. Following transformation of the synthetic plasmid into E. coli BL21(DE3), protein expression was verified by Western blot analysis. This study constructed the multi-epitope vaccine candidate rPRRSV-35N targeting NADC30-like and NADC34-like PRRSV strains. Its expressibility was preliminarily verified via molecular cloning and protein expression assays. Further in vivo studies are required to assess its protective efficacy.

PMID 42464250
Read full article →
PubMedActa paediatrica (Oslo, Norway : 1992)2026-07-17

Transient Tachypnea of the Newborn Following Planned Caesarean Births at a Tertiary Hospital in Northern Tanzania; A Prospective Cross-Sectional Study.

Shirima Febronia L FL, Andongolile Alice A, Mchome Bariki B, Keus Annemarie A et al.

To determine the burden of Transient Tachypnea of the Newborn in term neonates born by planned caesarean birth (CB) at ≥ 37 weeks gestational age (GA), their characteristics and treatment outcomes. Prospective cross-sectional study of neonates born by planned CB at ≥ 37 weeks GA at a tertiary hospital in Tanzania from September 2023 to February 2024. A total of 110 neonates (mean (SD) birth weight 3248 (±522) grams and median (IQR) GA 38 (38, 39) weeks) were enrolled in this study. Prevalence of TTN was 18/110 (16.4%). Of the neonates with TTN, 1/18 (5.6%) had persistent pulmonary hypertension (PPHN). Neonates with TTN were more often males and born at 37-38 weeks of gestation. Oxygen was administered in 17/18 (94.4%), CPAP in 1/18 (5.6%). Monitoring and treatment of TTN cases took place at the labour ward in 8/18 (44.4%) and at neonatal care unit in 10/18 (55.6%) neonates. TTN following planned CB is a notable cause of neonatal respiratory morbidity in this setting. Interventions for improving newborn outcomes following planned CB are recommended.

PMID 42464948
Read full article →
PubMedJournal of translational medicine2026-07-17

Systemic immune profiling of heterologous versus homologous boosting of COVID-19 vaccination.

Han Xu X, Jiang Hudachuan H, Zheng Hui H, Jin Pengfei P et al.

Compared with homologous boosting, heterologous boosting with a different COVID-19 vaccine following priming generates stronger antibody responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as variants, particularly for inactivated COVID-19 vaccine(CoronaVac). However, it is still unclear about the potential immune enhancement mechanism underlying heterologous boosting. In this study, we isolated spike protein binding-specific monoclonal antibodies at day 180 post a homologous booster with CoronaVac or a heterologous booster with Ad5-nCoV based on two-dose of CoronaVac using the single B cell sorting platform. Subsequently, we verified their neutralization activity to SARS-CoV-2 variants, germline gene sequences and affinity kinetics targeting SARS-CoV-2 NTD/RBD/S1. Additionally, we conducted an in-depth analysis of the immunological response characteristics, by integrating single-cell RNA/V(D)J sequencing(scRNA/ V(D)J-seq). Our study demonstrated that heterologous boosting with Ad5-nCoV elicited more mature B cells with higher affinity and activated more abundant immune-related pathways compared to the homologous boosting with CoronaVac. In addition, Ad5-nCoV boosting expanded unique clonal types of B and T cells, whereas CoronaVac boosting led to a small-sized clonal expansion. Furthermore, the utilization of germlines associated with neutralizing antibody were preferentially enriched in recipients with Ad5-nCoV boosting. Above all, our study gives insights for elaborating the systemic immune landscape of heterologous-boosting COVID-19 immunization by the novel single B cell sorting platform and scRNA/V(D)J-seq technology. NCT04892459.

PMID 42464341
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about polio vaccine